title: Inhibition of anti-V3 domain antibody binding to human immunodeficiency virus type-1-infected cells by sulfated polysaccharides.
abstract: The third variable domain (V3 domain) of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 is an immunodominant region. Anti-V3 domain antibodies neutralize both HIV-1 infection and syncytium formation. The V3 domain has a high density of positive charge which is a potential binding site for anti-HIV-1 sulfated polysaccharides. To investigate the inhibitory effect of sulfated polysaccharides on the binding of anti-V3 domain antibody, fluorescence-activating cell sorting analysis was performed using two kinds of antibodies, NEA9284 (purified, 0.25 micrograms/ml) and 0.5 beta (ascite, 2.0 mg/ml), and HIV-1-infected CEM cells. When the binding assay with a 1:100 dilution of each antibody was performed in the presence of dextran sulfate, heparin, and inositol hexasulfate at concentrations which are antiviral, the compounds did not inhibit the binding of either antibody. As the antibody concentration was decreased with higher dilution, dextran sulfate was able to reduce antibody binding by 50-60%. Thus, antagonism of anti-V3 domain antibody binding by sulfated polysaccharides is not as extensive as reported previously by several groups.
authors.affiliation: Department of Cell, Molecular, and Structural Biology, Northwestern University Medical School, Chicago, IL 60611, USA.
authors.forename: T
authors.initials: T
authors.lastname: Okada
authors.forename: B K
authors.initials: BK
authors.lastname: Patterson
authors.forename: M E
authors.initials: ME
authors.lastname: Gurney
mesh_terms: D000595:Amino Acid Sequence; D000906:Antibodies / Q000378:metabolism; D001666:Binding Sites, Antibody / Q000187:drug effects; D002460:Cell Line; D002809:Chondroitin Sulfates / Q000494:pharmacology*; D016264:Dextran Sulfate / Q000494:pharmacology*; D003911:Dextrans / Q000494:pharmacology; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D015497:HIV-1 / Q000502:physiology*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007294:Inositol / Q000494:pharmacology; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D010833:Phytic Acid / Q000494:pharmacology; D017354:Point Mutation; D011994:Recombinant Proteins / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D000906:Antibodies; D003911:Dextrans; D015699:HIV Envelope Protein gp120; D011994:Recombinant Proteins; D007294:Inositol; D010833:Phytic Acid; D006493:Heparin; D002809:Chondroitin Sulfates; D016264:Dextran Sulfate